Objective

The presentation will focus on the advances in regulatory diagnostic assay development which has enabled the delivery of companion and complementary diagnostics that allow the approval of targeted therapeutics across multiple indications. These advances will be show cased through specific case studies in oncology, immuno-oncology and inflammation. New horizons in diagnostic methodologies that enable more patients to benefit from life changing new medicines across multiple therapeutic areas will also be discussed.